NCT07408804Recruiting
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- 8 Apr 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Bangladesh Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07408804
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 8 Apr 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hepatocellular carcinoma with main trunk portal vein thrombosis,
- Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,
- Known allergy or intolerance to lenvatinib .
Other
- Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,
- Child Turcotte Pugh Score 10 ( C) or more,
- ALBI grade 3,
Who the study is looking for
- Age 18-75 years,
- Hepatocellular carcinoma, confirmed by dynamic CT scan / MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,
- At least one measurable lesion based on mRECIST criteria,
- ECOG performance status 0-2,
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Hepatology, Bangladesh Medical University Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.